FY2024 EPS Estimates for TSE:HLS Decreased by Stifel Canada

HLS Therapeutics Inc. (TSE:HLS) – Stifel Canada reduced their FY2024 earnings per share estimates for HLS Therapeutics in a note issued to investors on Tuesday, November 12th. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings per share of ($0.88) for the year, down from their prior estimate of ($0.86). The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($0.31) EPS.

Separately, Stifel Nicolaus dropped their price target on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.

HLS Therapeutics Price Performance

HLS opened at C$3.18 on Friday. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. HLS Therapeutics has a 1 year low of C$3.00 and a 1 year high of C$5.48. The stock’s 50 day simple moving average is C$3.55 and its 200 day simple moving average is C$3.55. The firm has a market cap of C$101.09 million, a price-to-earnings ratio of -3.15 and a beta of 1.07.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.